JAM
AUTL

Jupiter Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Jupiter Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-705,356
Closed -$4.13M – 265
2020
Q1 		$4.13M Hold
705,356
– – 0.18% 124
2019
Q4 		$9.31M Hold
705,356
– – 0.29% 99
2019
Q3 		$8.75M Buy
+705,356
New +$9.32M 0.29% 102

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Asset Management's AUTL Position: Q2 2020 in Review

Jupiter Asset Management sold out of Autolus Therapeutics (AUTL) in Q2 2020, closing a stake of 705,356 shares — an estimated $4.13M sold.

Jupiter Asset Management first reported a position in AUTL in Q3 2019 and held it in 3 quarters. The position peaked at $9.31M in Q4 2019. 50 funds tracked by Wall St. Rank hold AUTL as of Q2 2020.

  • Jupiter Asset Management reported no remaining Autolus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Jupiter Asset Management sold 705,356 Autolus Therapeutics shares in Q2 2020, an estimated $4.13M.
  • Jupiter Asset Management first reported a position in Autolus Therapeutics in Q3 2019 and held it in 3 quarters.
  • Jupiter Asset Management's Autolus Therapeutics position peaked at $9.31M in Q4 2019.
  • 50 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2020.

Based on Jupiter Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.